This is a preview of subscription content, log in via an institution to check access.
References
BioMarin Pharmaceutical Inc. BioMarin Submits U.S. Biologics License Application for Marketing Authorization of Aryplase for MPS VI. Media Release: 29 Nov 2004. Available from URL: http://www.bmrn.com
BioMarin Pharmaceutical Inc. FDA Accepts and Grants Six- Month Review for BioMarin’s Marketing Application for rhASB for MPS VI. Media Release: 1 Feb 2005. Available from URL: http://www.bmrn.com
BioMarin Pharmaceutical Inc. BioMarin Presents Positive Phase II Data on Aryplase for MPS VI. Media Release: 14 Mar 2003. Available from: URL: http://www.biomarinpharm.com
BioMarin Pharmaceutical Inc. BioMarin Announces Positive Phase 3 Data on Aryplase(TM) for MPS VI. Media Release: 3 Jun 2004. Available from URL: http://www.bmrn.com
BioMarin Pharmaceutical Inc. BioMarin Announces FDA Approval for Naglazyme. Media Release 1 Jun 2005. Available from URL: http://www.bmrn.com
BioMarin Pharmaceutical Inc. BioMarin Announces U.S. Launch of Naglazyme for MPS VI. Media Release: 21 Jun 2005. Available from URL: http://www.bmrn.com
BioMarin Pharmaceutical Inc. BioMarin Presents Positive Long-Term Results from Ongoing Phase 1 and Phase 2 Clinical Studies of Aryplase for MPS VI. Media Release: 5 Nov 2003. Available from URL: http://www.biomarinpharm.com
BioMarin Pharmaceutical Inc. BioMarin’s Phase 3 Extension Study of rhASB in MPS VI Demonstrates Additional Improvements in Endurance. Media Release: 9 Mar 2005. Available from URL: http://www.bmrn.com
Rights and permissions
About this article
Cite this article
Galsulfase. Drugs R D 6, 312–315 (2005). https://doi.org/10.2165/00126839-200506050-00008
Published:
Issue Date:
DOI: https://doi.org/10.2165/00126839-200506050-00008